45 completed, 31 recruiting, 29 terminated, 24 active not recruiting. 83 Phase 2, 71 Phase 1, 8 Not applicable, 5 Phase 3, 1 Early Phase 1.
Follow Carcinoma, Merkel Cell: new trials by email Literature Review of Carcinoma, Merkel Cell trials Research Report on Carcinoma, Merkel Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 50 | 2026-12-01 | 2026-09-17 |
| ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1 ASTX727 + retifanlimab - Merkel Cell Carcinoma, Merkel Cell Carcinoma, Stage III | Phase 1 / Phase 2 | Not yet recruiting | University of Wisconsin, Madison | 31 | 2026-10-01 | 2026-09-29 |
| A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors ARV-6723, Pembrolizumab, SOC - Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | Arvinas Inc. | 499 | 2026-07-29 | 2026-10-13 |
| A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21) Pembrolizumab - Malignant Neoplasm, Carcinoma, Merkel Cell | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 20 | 2026-06-23 | 2026-07-13 |
| Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cycles, Placebo NaCl 0.9% solution i.v. on day 1 of every 21 days cycle for 2 cycles. - Merkel Cell Carcinoma, Stage I, Merkel Cell Carcinoma, Stage II | Phase 2 | Recruiting | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 135 | 2026-05-29 | 2026-06-22 |
| TIL Therapy in cSCC and MCC LN-145, Cyclophosphamide, Fludarabine - Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma | Phase 2 | Recruiting | Karam Khaddour, MD, MS | 14 | 2026-02-10 | 2026-02-13 |
| IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC) IFx-Hu2.0, Pembrolizumab - Advanced Or Metastatic Merkel Cell Carcinoma | Phase 1 | Recruiting | TuHURA Biosciences, Inc. | 9 | 2026-01-27 | 2026-10-21 |
| The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas Cancer Therapeutic Procedure, Questionnaire Administration - Amyloidosis, Basal Cell Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 27 | 2025-12-18 | 2026-09-30 |
| Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma IFx-Hu2.0, Placebo, Pembrolizumab - Advanced Or Metastatic Merkel Cell Carcinoma | Phase 2 / Phase 3 | Recruiting | TuHURA Biosciences, Inc. | 118 | 2025-12-11 | 2026-04-17 |
| Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors 225Ac-ETN029, 111In-ETN029 - Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung | Phase 1 | Recruiting | Novartis Pharmaceuticals | 116 | 2025-10-16 | 2026-09-22 |
| Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors Tarlatamab, Concurrent Radiation Therapy, Sequential Radiation therapy - Melanoma, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Recruiting | University of Arizona | 30 | 2025-09-08 | 2026-10-06 |
| A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors AZD6750, rilvegostomig - Melanoma, Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 120 | 2025-07-29 | 2026-10-08 |
| Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype percutaneous, laparoscopic or laparotomy lesion electrochemotherapy - Primary Visceral Tumors of Any Histotype, Visceral Lesions | Not applicable | Recruiting | Istituto Oncologico Veneto IRCCS | 24 | 2025-07-23 | 2026-04-13 |
| Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 ) 225Ac-SSO110 + SoC, Atezolizumab, Durvalumab - Small Cell Lung Cancer Extensive Stage, Merkel Cell Carcinoma | Phase 1 / Phase 2 | Terminated | Ariceum Therapeutics GmbH | 2 | 2025-07-01 | 2026-02-05 |
| Exploring Merkel Cell Carcinoma Clinical Trial Engagement Patterns Merkel Cell Carcinoma | Not yet recruiting | Power Life Sciences Inc. | 500 | 2024-10-01 | 2023-09-15 | |
| Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 16 | 2024-07-24 | 2026-10-14 |
| Identification and Characterization of Circulating Tumor Cells Before and After Treatment (Surgery and Radiotherapy) in a Cohort of Patients Treated for Resectable Stage I-III Merkel Cell Carcinoma Blood Test - Merkel Cell Carcinoma | Not yet recruiting | University Hospital, Montpellier | 25 | 2024-07-01 | 2024-06-13 | |
| Exercise to Boost Response to Checkpoint Blockade Immunotherapy Exercise Test - Cutaneous Melanoma, Cutaneous Squamous Cell Carcinoma | Not applicable | Active not recruiting | AdventHealth Translational Research Institute | 12 | 2024-06-03 | 2026-03-25 |
| Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial Avelumab, Biopsy Procedure, Biospecimen Collection - Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 50 | 2024-05-21 | 2026-07-31 |
| Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination - Merkel Cell Carcinoma | Phase 2 | Recruiting | Melanoma Institute Australia | 20 | 2024-03-11 | 2026-02-17 |
Showing 20 of 147. Sign in to see all of them.
Melanoma (61) · Carcinoma, Non-Small-Cell Lung (37) · Carcinoma, Renal Cell (36) · Uterine Cervical Neoplasms (30) · Small Cell Lung Carcinoma (28) · Stomach Neoplasms (28) · Carcinoma, Hepatocellular (25) · Carcinoma, Transitional Cell (25) · Squamous Cell Carcinoma of Head and Neck (23) · Triple Negative Breast Neoplasms (22) · Neoplasm Metastasis (21) · Carcinoma, Basal Cell (20) · Skin Neoplasms (17) · Colorectal Neoplasms (16)
Adenocarcinoma (147) · DNA Virus Infections (147) · Infections (147) · Neoplasms by Histologic Type (147) · Neoplasms, Germ Cell and Embryonal (147) · Neoplasms, Glandular and Epithelial (147) · Neoplasms, Nerve Tissue (147) · Neuroectodermal Tumors (147) · Polyomavirus Infections (147) · Tumor Virus Infections (147) · Virus Diseases (147) · Carcinoma, Neuroendocrine (144) · Carcinoma (142) · Neuroendocrine Tumors (141) · Neoplasms (131)
pembrolizumab (30) · avelumab (21) · Nivolumab (20) · Ipilimumab (10) · Cyclophosphamide (9) · Radiotherapy (9) · atezolizumab (8) · cemiplimab (7) · Specimen Handling (6) · fludarabine (6) · Biopsy (5) · Interleukin-2 (5) · Magnetic Resonance Spectroscopy (5) · Radiation (5) · aldesleukin (5)
National Cancer Institute (NCI) (10) · Memorial Sloan Kettering Cancer Center (5) · Fate Therapeutics (4) · Fred Hutchinson Cancer Center (4) · H. Lee Moffitt Cancer Center and Research Institute (4) · ImmunityBio, Inc. (4) · Incyte Biosciences International Sàrl (4) · Incyte Corporation (4) · TuHURA Biosciences, Inc. (4) · M.D. Anderson Cancer Center (3) · Mayo Clinic (3) · 4SC AG (2) · AbbVie (2) · Dana-Farber Cancer Institute (2) · Melanoma Institute Australia (2)
United States (110) · Australia (20) · France (19) · Spain (16) · Italy (12) · Canada (11) · Germany (9) · Belgium (8) · Japan (8) · United Kingdom (8) · Switzerland (6) · Netherlands (5) · Austria (4) · South Korea (4) · Finland (3)
Andrew S Brohl, MD (3) · Aude Chapuis (2) · Evan J Lipson (2) · John E. Janik, MD (2) · Paul Nghiem (2) · Robert Haddad, MD (2) · Shailender Bhatia (2) · Shailender Bhatia, MD (2) · Afshin Shafie, MD (1)
PMID 42580817, PMID 21757257, PMID 25900182, PMID 27093365, PMID 27592805, PMID 29273043, PMID 29347993, PMID 29445030, PMID 29512061, PMID 29566106, PMID 29914528, PMID 30304652, PMID 30726175, PMID 31553054, PMID 31689874, PMID 32375680, PMID 32414862, PMID 32430019, PMID 32472503, PMID 32503950, PMID 32770720, PMID 32819975, PMID 32938212, PMID 33219092, PMID 33879601, PMID 33929874, PMID 34216247, PMID 34301810, PMID 34329846, PMID 34519839, PMID 34627593, PMID 34921021, PMID 35034046, PMID 35046056, PMID 35389428, PMID 35444059, PMID 35507536, PMID 36821617, PMID 37055772, PMID 37131154, PMID 37451295, PMID 37683276, PMID 37711623, PMID 37848259, PMID 37865395, PMID 38126779, PMID 38252910, PMID 38618958, PMID 38618960, PMID 39021272
2018 (5), P30CA015704 (5), 2014 (3), 2016 (3), 2019 (3), 2023 (3), K24CA139052 (2), U10CA032102 (2), UM1CA186691 (2), N01CM62206 (1), N01CM62207 (1), P01CA225517 (1), P30CA016672 (1), R01CA176841 (1), U01CA062461 (1)